Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 3;7(7):CD014907.
doi: 10.1002/14651858.CD014907.pub2.

Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol

Corynne Marchal  1 , Emeline Orillard  2 , François Calais  3 , Virginie Westeel  2   4
Affiliations

Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol

Corynne Marchal et al. Cochrane Database Syst Rev. .

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the effectiveness and safety of immune checkpoint inhibitors (ICI) as monotherapy or in combination compared to standard of care for elderly people (≥ 65 years) with non-small cell lung cancer (NSCLC).

PubMed Disclaimer

Conflict of interest statement

CM has declared that she has no conflict of interest. She is Managing Editor for the Cochrane Lung Cancer Group and was not involved in the editorial process.

EO has declared that she has no conflict of interest.

FC has declared that he has no conflict of interest. He is Information Specialist for the Cochrane Lung Cancer Group and was not involved in the editorial process

VW has received payment for consultancy fees from Amgen, for board membership from Amgen, AstraZeneca and Ipsen Biopharmaceuticals, Inc; for speakers bureaus from Amgen, AstraZeneca, Bristol‐Myers Squibb, Merck Sharp and Dohme, Roche and Sanofi ; for scientific committees from Amgen, AstraZeneca, Merck Sharp and Dohme, Roche; and for travel accommodations and meeting expenses from Amgen, AstraZeneca, Bristol Myers Squibb, Janssen Pharmaceuticals, Merck Sharp & Dohme, Roche, and Sanofi. VW is chest physician at the University Hospital of Besancon, France, and she is Co‐ordinating Editor for the Cochrane Lung Cancer Group and was not involved in the editorial process.

Figures

1
1
Mechanisms of action of anti‐PD‐L1 and anti‐CTLA‐4 antibodies. Red line: inhibition of the checkpoint protein. Figure drawn by Emeline Orillard. CD: cluster of differentiation / CTLA‐4: cytotoxic T lymphocyte associated protein‐4 / MHC: major histocompatibility complex / PD‐L1: programmed cell death ligand‐1 / TCR: T cell receptor.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD014907

References

Additional references

Aiello 2019
    1. Aiello A, Farzaneh F, Candore G, Caruso C, Davinelli S, Gambino CM, et al. Immunosenescence and its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention. Frontiers in Immunology 2019;10:2247. - PMC - PubMed
Antonia 2017
    1. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. New England Journal of Medicine 2017;377:1919-29. - PubMed
Antonia 2018
    1. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. New England Journal of Medicine 2018;379:2342-50. - PubMed
Antonia 2019
    1. Antonia SJ, Borghaei H, Ramalingam SS, Horn L, De Castro Carpeno J, Pluzanski A, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncology 2019;20:1395–408. - PMC - PubMed
Barta 2019
    1. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Annals of Global Health 2019;85:8. - PMC - PubMed
Bodor 2020
    1. Bodor JN, Boumber Y, Borghaei H. Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC). Cancer 2020;126:260-70. - PMC - PubMed
Borghaei 2015
    1. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced non-squamous non-small cell lung cancer. New England Journal of Medicine 2015;373:1627–39. - PMC - PubMed
Boutron 2021
    1. Boutron I, Page MJ, Higgins JPT, Altman DG, Lundh A, Hróbjartsson A. Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.
Boutros 2016
    1. Boutros C, Tarhini A, Routier E, Lambotte O, Leroy Ladurie F, Carbonnel F, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews Clinical Oncology 2016;13:473-86. - PubMed
Brahmer 2015
    1. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. New England Journal of Medicine 2015;373:123–35. - PMC - PubMed
Bray 2018
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer Journal for Clinicians 2018;68:394-424. - PubMed
Brockhaus 2014
    1. Brockhaus AC, Bender R, Skipka G. The Peto odds ratio viewed as a new effect measure. Statistics in Medicine 2014;33:4861-74. - PubMed
CheckMate 816
    1. Bristol-Myers Squibb. Neoadjuvant opdivo (nivolumab) plus chemotherapy significantly improves pathologic complete response in patients with resectable non-small cell lung cancer in phase 3 CheckMate-816 trial. https://news.bms.com/news/details/2021/Neoadjuvant-Opdivo-nivolumab-Plus....
Chen 2013
    1. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1-10. - PubMed
Covidence  [Computer program]
    1. Covidence. Version accessed 4 February 2020. Melbourne, Australia: Veritas Health Innovation, Available at covidence.org.
de Groot 2018
    1. Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Translational Lung Cancer Research 2018;7:220-33. - PMC - PubMed
Deeks 2021
    1. Deeks JJ, Higgins JPT, Altman DG, editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88. - PubMed
Dunn 2002
    1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology 2002;3:991-8. - PubMed
Dunn 2004
    1. Dunn GP, Old LJ, Schreiber RB. The three Es of cancer immunoediting. Annual Review of Immunology 2004;22:329-60. - PubMed
Eisenhauer 2009
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (Version 1.1). European Journal of Cancer 2009;45:228-47. - PubMed
Ettinger 2019
    1. Ettinger DS, Wood DE, Aggarwal C, Aisner DL, Akerley W, Bauman JR, et al. NCCN guidelines insights: non-small cell lung cancer, version 1.2020. National Comprehensive Cancer Network 2019;17:1464-72. - PubMed
Felip 2018
    1. Felip E, Brahmer J, Broderick S, Swanson S, Awad M, Mitsudomi T, et al. CheckMate 816: A phase 3 trial of neoadjuvant nivolumab plus ipilimumab or chemotherapy vs chemotherapy in early-stage NSCLC. Journal of Thoracic Oncology 2018;13(10 Suppl):S831-2.
Ferrara 2017
    1. Ferrara R, Mezquita L, Auclin E, Chaput N, Besse B. Immunosenescence and immune checkpoint inhibitors in non-small cell lung cancer patients: does age really matter? Cancer Treatment Reviews 2017;60:60-8. - PubMed
Ferrara 2020
    1. Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, et al. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer (Review). Cochrane Database of Systematic Reviews 2020, Issue 12. Art. No: CD013257. [DOI: 10.1002/14651858.CD013257.pub2] - DOI - PMC - PubMed
Ferrara 2021
    1. Ferrara R, Naigeon M, Auclin E, Duchemann B, Cassard L, Jouniaux JM, et al. Circulating T-cell immunosenescence in advanced non-small cell lung cancer patients treated with single agent PD-1/PD-L1 inhibitors or platinum-based chemotherapy. Clinical Cancer Research 2021;27:492–503. - PubMed
Fiteni 2016
    1. Fiteni F, Anota A, Bonnetain F, Oster J-P, Pichon E, Wislez M, et al. Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy. European Respiratory Journal 2016;48:861-72. - PubMed
Gandhi 2018
    1. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. New England Journal of Medicine 2018;378:2078-92. - PubMed
Goldstraw 2016
    1. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt W, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. Journal of Thoracic Oncology 2016;11:39-51. - PubMed
Gomes 2020
    1. Gomes F, Wong M, Battisti NM, Kordbacheh T, Kiderlen M, Greystoke A. Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper. British Journal of Cancer 2020;123:874–84. - PMC - PubMed
GRADEpro GDT [Computer program]
    1. GRADEpro GDT. Version accessed 4 May 2021. Hamilton (ON): McMaster University (developed by Evidence Prime), 2020. Available at gradepro.org.
Granier 2020
    1. Granier C, Gey A, Roncelin S, Weiss L, Paillaud E, Tartour E. Immunotherapy in older patients with cancer. Biomedical Journal 2020 Jul 26 [Epub ahead of print]. [DOI: 10.1016/j.bj.2020.07.009] - DOI - PMC - PubMed
Hellmann 2019
    1. Hellmann MD, Paz‐Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. New England Journal of Medicine 2019;381:2020-31. - PubMed
Herbst 2016
    1. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540–50. - PubMed
Herbst 2020
    1. Herbst RS, Giaccone G, Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC. New England Journal of Medicine 2020;383:1328-39. - PubMed
Higgins 2002
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58. - PubMed
Higgins 2021a
    1. Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.
Higgins 2021b
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook. - PMC - PubMed
Howlader 2011
    1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER cancer statistics review, 1975-2008, National Cancer Institute. Based on November 2010 SEER data submission, posted to the SEER web site, 2011. seer.cancer.gov/csr/1975_2008/.
Huff 2019
    1. Huff WX, Kwon JH, Henriquez M, Fetcko K, Dey M. The evolving role of CD8+CD28− immunosenescent T Cells in cancer immunology. International Journal of Molecular Sciences 2019;20:2810. - PMC - PubMed
Kerr 2021
    1. Kerr KM, Bibeau F, Thunnissen E, Botling J, Ryska A, Wolf J, et al. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. Lung Cancer 2021;154:161-75. - PubMed
Lefebvre 2021
    1. Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf MI, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.
Lopez‐Otın 2013
    1. Lopez-Otın C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell 2013;153:1194–217. - PMC - PubMed
Luciani 2020
    1. Luciani A, Marra A, Toschi L, Cortinovis D, Fava S, Filipazzi V, et al. Efficacy and safety of anti-PD-1 immunotherapy in patients aged ≥ 75 years with non-small-cell lung cancer (NSCLC): an Italian, multicenter, retrospective study. Clinical Lung Cancer 2020;21:e567-71. - PubMed
Martins 2019
    1. Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nature Reviews Clinical Oncology 2019;16:563-80. - PubMed
Mazieres 2021
    1. Mazieres J, Rittmeyer A, Gadgeel S, Hida T, Gandara DR, Cortinovis DL, et al. Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials. Journal of Thoracic Oncology 2021;16(1):140-150. - PubMed
Nishino 2013
    1. Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi S. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clinical Cancer Research 2013;19:3936-43. - PMC - PubMed
Pallis 2014
    1. Pallis AG, Gridelli C, Wedding U, Faivre-Finn C, Veronesi G, Jaklitsch M, et al. Management of elderly patients with NSCLC; updated expert’s opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. Annals of Oncology 2014;25:1270–83. - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:815-34. - PubMed
Patel 2015
    1. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Molecular Cancer Therapeutics 2015;14:847-56. - PubMed
Pauken 2019
    1. Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse events following cancer immunotherapy: obstacles and opportunities. Trends in Immunology 2019;40:511-23. - PMC - PubMed
Paz‐Ares 2018
    1. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. New England Journal of Medicine 2018;379:2040-51. - PubMed
Paz‐Ares 2021
    1. Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncology 2021 Jan 18 [Epub ahead of print]. [DOI: 10.1016/S1470-2045(20)30641-0] - DOI - PubMed
Planchard 2018
    1. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2018;29:iv192–237. - PubMed
Postmus 2017
    1. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2017;28:iv1–21. - PubMed
Postow 2018
    1. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. New England Journal of Medicine 2018;378:158-68. - PubMed
Quoix 2011
    1. Quoix E, Zalcman G, Oster J-P, Westeel V, Pichon E, Lavolé A, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011;378:1079-88. - PubMed
Reck 2016
    1. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. New England Journal of Medicine 2016;375:1823-33. - PubMed
Reck 2019
    1. Reck M, Rodrıguez-Abreu D, Robinson AG, Rina Hui R, Csoszi T, Fulop A, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. Journal of Clinical Oncology 2019;37:537-46. - PubMed
Review Manager 2020 [Computer program]
    1. Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.
Rittmeyer 2017
    1. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255–65. - PMC - PubMed
Rodriguez‐Abreu 2020
    1. Rodriguez-Abreu D, Johnson ML, Hussein MA, Cobo M, Patel AJ, Secen NM, et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). Journal of Clinical Oncology 2020;38(15 Suppl):9503.
Sacher 2013
    1. Sacher AG, Le LW, Leighl NB, Coate LE. Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC? Journal of Thoracic Oncology 2013;8:366-8. - PubMed
Schünemann 2021
    1. Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.
SEER 2021
    1. Surveillance, Epidemiology and End Results Program. SEER 18 2010–2016, All Races, Both Sexes by SEER Summary Stage 2000. seer.cancer.gov/statfacts/html/lungb.html (accessed 9 March 2021).
Seymour 2017
    1. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncology 2017;18:e143-52. - PMC - PubMed
Shenoy 2015
    1. Shenoy P, Harugeri A. Elderly patients' participation in clinical trials. Perspectives in Clinical Research 2015;6:184-9. - PMC - PubMed
SIOG 2021
    1. International Society of Geriatric Oncology. Defining the elderly. www.siog.org/content/defining-elderly (accessed 1 February 2021).
Socinski 2018
    1. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic non-squamous NSCLC. New England Journal of Medicine 2018;378:2288-301. - PubMed
Takigawa 2020
    1. Takigawa N, Ochi N, Nakagawa N, Nagasaki Y, Taoka M, Ichiyama N, et al. Do elderly lung cancer patients aged ≥75 years benefit from immune checkpoint inhibitors? Cancers 2020;12:1995. - PMC - PubMed
Tierney 2007
    1. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16. - PMC - PubMed
Torre 2016
    1. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Advances in Experimental Medicine and Biology 2016;893:1-19. - PubMed
Wang 2018
    1. Wang DY, Salem J-E, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncology 2018;4:1721-8. - PMC - PubMed
West 2019
    1. West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology 2019;20:924–37. - PubMed
Xia 2019
    1. Xia A, Zhang Y, Xu J, Yin T, Lu XJ. T cell dysfunction in cancer immunity and immunotherapy. Frontiers in Immunology 2019;10:1719. - PMC - PubMed
Xu 2018
    1. Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 2018;363:k4226. - PMC - PubMed
Yan 2020
    1. Yan X, Tian X, Wu Z, Han W. Impact of age on the efficacy of immune checkpoint inhibitor-based combination therapy for non-small-cell lung cancer: a systematic review and meta-analysis. Frontiers in Oncology 2020;10:1671. - PMC - PubMed
Yu 2019
    1. Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y, et al. Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: a meta-analysis and individual patient-level analysis. JAMA Network Open 2019;2:e196879. - PMC - PubMed
Zhou 2013
    1. Zhou JX, Yang H, Deng Q, Gu X, He P, Lin Y, et al. Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages. Annals of Oncology 2013;24:1319–25. - PubMed

MeSH terms

Substances

LinkOut - more resources